Farmas USA

NVAX velas 1h

Ya sabemos que todo esto esta planeado desde largo tiempo atras pero verlo .. ouch, escuece ..

http://stocknewsflow.com/1000694_000114420416134953_0001144204-16-134953

Yo creo sinceramente que hemos tocado fondo o estamos muy cerca. A partir de ahora creo que es facil verla en 3,5 como mínimo a mitad del año que viene.

NVAX
AVIR datos fase 2 RSV a final de año.

Announced Completion of Enrollment in the Phase 2a RSV Challenge Study of BTA585. Today, the Company announced the completion of patient enrollment in the final cohort (600 mg bid) in the Phase 2a trial in healthy volunteers intranasally challenged with RSV. Top-line data from this trial is expected around the end of the year.

Phase 2a Efficacy Study of BTA585 for the Treatment of Respiratory Syncytial Virus (RSV) Infections that is designed to evaluate the safety, pharmacokinetics, and antiviral activity of orally-dosed BTA585 in healthy volunteers challenged intranasally with RSV.

Si no recuerdo mal eso seria el equivalente en NVAX a Abril 2013 cuando libero los resultados en una fase 2a RSV mujeres en edad fertil. 

Ojo con juguetear con DVAX, por patron ayer se caso un harami bajista.

Shooting star en AMRN en lo alto de impulso alcista, corto potencial.

GILD

Buena temporada de FAILS que lleva:

TLR7 HBV - FAIL
Simtuzumab - FAIL
Eleclazine VF/VT - FAIL
MMP9 IBD - FAIL
Momelotinib - essentially FAIL

Me ha hecho gracia el artículo del bastardo sobre este tema:

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

https://www.thestreet.com/story/13897080/1/hey-gilead-stop-developing-drugs-and-start-buying-biotech-companies-now.html

ZIOP

ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer

— Data to Be Presented at the 21st Society for Neuro-Oncology Annual Meeting —

— Non-clinical Study Supports Initiation of New Clinical Trial of Ad-RTS-hIL-12 in Pediatric Brain Tumors —

http://ir.ziopharm.com/releasedetail.cfm?ReleaseID=999896

ZIOP ahora + 25% en pre. Si aguanta, venderé hoy un paquete, pero no creo porque poco volumen
Gene therapy candidate using ZIOPHARM's RheoSwitch shows encouraging results in early-stage brain cancer study; shares up 25% premarket
http://www.seekingalpha.com/news/3225323